Form 4: Travere Therapeutics Director Sells Shares

Travere Therapeutics Director Timothy Coughlin exercised stock options and subsequently sold 18,000 shares of common stock for a profit.

Summary

• Timothy Coughlin, a Director at Travere Therapeutics, Inc. (TVTX), reported transactions on October 31, 2025.
• Coughlin exercised options to acquire 8,000 shares of common stock at an exercise price of $16.33 per share.
• Additionally, Coughlin exercised options to acquire 10,000 shares of common stock at an exercise price of $17.44 per share.
• Immediately following the option exercises, Coughlin sold 18,000 shares of common stock at a weighted average price of $35.0334 per share.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2025.
• Following these transactions, Coughlin's direct beneficial ownership of common stock is 55,500 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the transaction was pre-planned under a Rule 10b5-1 plan, which mitigates concerns about the timing or motivation of the sale. It represents a routine liquidity event for the director.

Positives

• The Director realized a significant profit from exercising stock options and selling shares, with the sale price of $35.0334 substantially higher than the exercise prices of $16.33 and $17.44.
• The transaction was conducted under a pre-arranged Rule 10b5-1(c) plan, indicating a structured approach to share disposition rather than a reaction to immediate market conditions or non-public information.

Negatives

• An insider (Director) reducing their direct ownership by selling 18,000 shares could be perceived as a slight negative signal by some investors, despite the pre-planned nature of the sale.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider sale as a slight negative signal, but the pre-planned nature under a 10b5-1 plan generally reduces concerns about its implications for the company's future prospects.
• Management: The transaction allows the director to realize value from their equity compensation in a compliant and transparent manner.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director exercised stock options and subsequently sold the acquired shares under a pre-arranged Rule 10b5-1 plan. Such transactions are typically for personal financial planning and liquidity, rather than a reflection of new material information about the company's performance or outlook. While insider sales can sometimes be a bearish signal, the pre-planned nature mitigates this. Therefore, this specific filing alone does not warrant a change in investment recommendation, suggesting a 'hold' position based solely on this information.

Keywords

Travere Therapeutics, TVTX, Insider Trading, Form 4, Stock Options, Share Sale, Director, 10b5-1 Plan